Embla Medical hf

As of June 30, 2026, Embla Medical hf carries a market capitalization of 11.59B, placing it among publicly traded companies globally. Its enterprise value stands at 14.47B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Embla Medical hf's next confirmed earnings release is scheduled for February 2, 2027.

As of June 30, 2026, Embla Medical hf has 425.91M shares outstanding.

As of June 30, 2026, Embla Medical hf trades at a trailing price-to-earnings ratio of 19.79. The price-to-sales ratio is 1.80, and the price-to-book ratio stands at 1.92.

As of June 30, 2026, Embla Medical hf trades at an EV/EBITDA multiple of 11.52 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.26 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 17.04 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Embla Medical hf trades at an EV/FCF ratio of 21.10, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 14.47B versus a market cap of 11.59B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Embla Medical hf maintains a current ratio of 1.25, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 57.66, indicating elevated leverage, while an interest coverage ratio of 9.59 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Embla Medical hf posted a return on equity (ROE) of 10.36, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 7.12 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 5.38, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 7.45, useful for judging operating efficiency across full business cycles. The company generates approximately 1.54M in revenue per employee across its workforce of 4,163.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.35 indicates how many times Embla Medical hf sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Embla Medical hf recorded 169.51M in income tax expense. That works out to an effective tax rate of 22.42, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 756.03M, leaving 582.18M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Embla Medical hf's stock has declined approximately 18.61% over the past 52 weeks. The 50-day moving average sits at 28.21, while the 200-day moving average is 31.27.

Over the twelve months ended June 30, 2026, Embla Medical hf generated 6.41B in revenue and converted that into 582.18M in net income, yielding earnings per share of 1.38. EBITDA reached 1.26B, while operating income came in at 849.17M.

As of June 30, 2026, Embla Medical hf holds 646.15M in cash and equivalents against 3.49B in total debt, resulting in a net debt position of 1.71B. Total book value stands at 6.02B, with working capital of 615.59M providing operational flexibility.

Embla Medical hf produced 777.93M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -193.75M in capital expenditures, free cash flow totaled 584.18M - equivalent to 1.38 per share.

Over the twelve months ended June 30, 2026, Embla Medical hf posted a gross margin of 62.20, reflecting its pricing power and cost economics. The operating margin of 13.25 and net profit margin of 9.08 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 5.07, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 3.65, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Embla Medical hf shareholders.

Embla Medical hf's most recent stock split took place on September 8, 2005 with a 59:60 split ratio.

As of June 30, 2026, Embla Medical hf has an Altman Z-Score of 4.84, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.